Off-the-shelf stem cell therapy for type 1 diabetes yields more positive results
Elizabeth Cooney, a cardiovascular disease reporter at STAT, recently covered the groundbreaking development in diabetes treatment involving an investigational off-the-shelf stem cell therapy. According to Vertex Pharmaceuticals, twelve individuals with type 1 diabetes who underwent this therapy were able to produce their own insulin and maintain healthy blood glucose levels for at least one year. Notably, after three months, none of the participants experienced severe episodes of low blood sugar, and after 12 months, 10 out of the 12 no longer required insulin injections.
The study, presented at the American Diabetes Association’s scientific meeting and published in the New England Journal of Medicine, provides an update on previous research that followed these participants for a shorter duration. All individuals involved in the study received a full dose of the therapy, which is now known as zimislecel (previously VX-880).
Zimislecel is derived from a stem cell line cultivated in a laboratory, with the intention of differentiating into insulin-producing cells. The therapy aims to provide individuals with new islet cells that can generate insulin, effectively replacing their malfunctioning natural islet cells affected by diabetes.
The results of this study offer promising prospects for individuals with type 1 diabetes, potentially revolutionizing the treatment landscape for this chronic condition. The ability to produce insulin independently and maintain stable blood glucose levels represents a significant advancement in diabetes management.
However, access to the full article detailing this groundbreaking research is exclusive to STAT+ subscribers. To unlock the complete story and access daily coverage and analysis of the biotech sector, interested readers are encouraged to subscribe to STAT+ for comprehensive insights into this innovative therapy and its implications for diabetes treatment.
